Lymphosarcoma in cattle may be sporadic or result from infection with bovine leukemia virus (BLV); the latter is often referred to as an enzootic bovine leukosis. Sporadic lymphosarcoma in cattle is unrelated to infection with BLV. Despite the lack of association, animals with sporadic lymphosarcoma may possibly be infected with the virus. Sporadic lymphosarcoma manifest in 3 main forms: juvenile, thymic, and cutaneous. Juvenile lymphosarcoma occurs most often in animals <6 mo of age, thymic lymphosarcoma affects cattle 6–24 mo of age, and cutaneous lymphosarcoma is most common in cattle 1–3 yr of age.
Etiology, Transmission, and Epidemiology
Enzootic bovine leukosis is caused by BLV, an exogenous C-type oncogenic retrovirus of the BLV-human T-lymphotropic virus group. BLV has a stable genome, does not cause chronic viremia, and has no preferred site of proviral integration. Despite the lack of preferred proviral integration sites, the tumors generated by the virus in a single individual are typically monoclonal and have a single integration site. The virus escapes the immune response by low levels of viral replication. It appears that replication is blocked at the transcriptional level, but the mechanism is not completely understood.
The prevalence of BLV infection varies from country to country. Many European countries, Australia, and New Zealand have eradication programs in place that have led to negligible rates of BLV infection. Although voluntary control programs are in place in the USA, prevalence is high compared to much of the rest of the world. The most recent surveys in the USA estimate that 44% of dairy and 10% of beef cattle are infected with the virus. Prevalence tends to increase on dairies with increasing herd size, while the converse is true in beef cattle. In general, the prevalence of viral infection increases with age.
Cattle are infected with BLV through the transfer of blood and blood products that contain infected lymphocytes. Once infected, cattle develop a lifelong antibody response, primarily to the gp51 envelope protein and the p24 capsid protein. B lymphocytes harbor the integrated provirus but rarely express viral proteins on their cell surface. The exact site of viral replication and expression that drives the immune response remains elusive.
Under experimental conditions most routes of viral exposure can successfully transmit infection. However, many of these settings are unlikely to be encountered naturally. Many bodily fluids, including urine, feces, saliva, respiratory secretions, semen, uterine fluids, and embryos, have been examined for their ability to transmit BLV and are considered to be noninfectious. Only on rare occasion has virus been found in these fluids. Colostrum from BLV-positive cows contains virus and has been found to be infectious experimentally. However, colostrum also contains large amounts of antibody and it is believed that the protective effects of colostral antibody outweigh the infectious potential when colostrum is administered in a normal fashion.
The majority of BLV transmission is horizontal. Close contact between BLV-negative and BLV-positive cattle is thought to be a risk factor. Many common farm practices have been implicated in viral transmission, including tattooing, dehorning, rectal palpation, injections, and blood collection. Vectors such as tabanids and other large biting flies also may transmit the virus. Vertical transmission may occur transplacentally from an infected dam to her fetus, intrapartum by contact with infected blood, or postpartum from the dam to the calf through the ingestion of infected colostrum. Any material that is blood contaminated or lymphocyte rich has the potential to infect animals with BLV.
There are 3 main outcomes in cattle infected with BLV. The majority of animals remain persistently infected with no outward signs of infection. Approximately 29% of BLV-infected cattle develop persistent lymphocytosis, while <5% of BLV-infected cattle develop lymphosarcoma.
Persistent lymphocytosis is sometimes referred to as a preneoplastic syndrome, but there is no convincing evidence that affected cattle have an increased risk of developing lymphosarcoma. The lymphocytes present in persistent lymphocytosis are not neoplastic, although they may have mild reactive changes consistent with normal blood smears in cattle. Persistent lymphocytosis is considered a benign condition associated with BLV infection. For this reason it is often overlooked. However, these cows may serve as a reservoir of infection. The increased lymphocyte count is attributed to a 45-fold increase of infected CD5+ and a 99-fold increase in infected CD5− B cells. It has been suggested that cows with persistent lymphocytosis may be at greater risk for passing BLV infection on to their calves in utero and may show decreased milk production and alteration of milk components.
Lymphosarcoma is rarely seen in animals <2 yr of age and is most common in the 4- to 8-yr age group. Less than 5% of BLV-infected cattle develop lymphosarcoma. Lymphosarcoma, including both sporadic and enzootic forms, is one of the main causes of condemnation at slaughter.
Clinical signs associated with the development of lymphosarcoma are highly variable, as the affected organ will dictate the predominant clinical signs.
Juvenile lymphosarcoma is often characterized by a sudden onset of diffuse lymphoid hyperplasia with or without visceral organ involvement. Weight loss, fever, tachycardia, dyspnea, bloat, and posterior paresis have all been described with this form of lymphosarcoma. Profound lymphocytosis (>50,000/μL) often accompanies this fatal form of bovine lymphosarcoma. Thymic lymphosarcoma may involve the cervical or intrathoracic thymus, or both. Clinical signs associated with this form of lymphosarcoma depend heavily on the location and size of the tumor. A cervical swelling may be evident. Dyspnea, bloat, jugular distention, tachycardia, anterior edema, and fever have been documented. The affected cell population is an immature, poorly differentiated lymphocyte. Cutaneous lymphosarcoma presents as cutaneous plaques, 1–5 cm in diameter, on the neck, back, rump, and thighs. Regional lymph nodes may also be enlarged. This form of lymphosarcoma may undergo spontaneous remission; however, relapses may occur.
Animals with BLV-associated lymphosarcoma commonly show lesions in the central or peripheral lymph nodes lead ing to lymphadenopathy. Lesions of the abomasum may lead to signs of cranial abdominal pain, melena, or abomasal outflow obstruction. Pelvic limb paresis progressing to paralysis can occur in animals with extradural spinal lesions. Retrobulbar lesions will cause protrusion of the globe resulting in exposure keratitis and eventually proptosis. Lesions of the right atrium may be mild and undetectable clinically, or may cause arrhythmias, murmurs, or heart failure. Uterine lesions may lead to reproductive failure or abortion. Lesions of the internal organs typically involve the spleen, liver, or kidneys and ureters. Lesions of the spleen are often initially asymptomatic, but may result in rupture of the spleen and exsanguination into the peritoneal cavity. Lymphosarcoma of the liver is often asymptomatic but may lead to jaundice and liver failure. Disease of the kidney and ureter can lead to abdominal pain and the subsequent development of hydroureter or hydronephrosis and clinical signs associated with renal failure.
Lymphosarcoma may appear as yellow-tan discrete nodular masses or a diffuse tissue infiltrate. The latter pattern results in an enlarged, pale organ and can be easily misinterpreted as a degenerative change rather than neoplasia. Histologically, the tumor masses are composed of densely packed, monomorphic lymphocytic cells.
Lymphosarcoma is often included on the differential list for many diseases because of the wide range of clinical findings. Diagnosis of viral infection is made by serology or virology, persistent lymphocytosis is identified by hematology, and neoplastic tumors are identified by histologic examination of biopsies. Positive serology or virology for BLV confirms viral infection but not the presence of lymphosarcoma.
Serology is the most common and reliable way to diagnose infection with BLV. Agar gel immunodiffusion is still recognized by most countries as the official import/export test, but ELISA is used most commonly for routine diagnostic use. Serology is unreliable in calves that have ingested colostrum from BLV-positive cows due to the passive acquisition of maternal antibodies that typically wane by 4–6 mo of age. PCR is a sensitive and specific assay for diagnosis of BLV infection in peripheral blood lymphocytes. This test can identify proviral DNA of BLV in the lymphocytes of infected animals and differentiate positive from negative calves in the presence of maternal antibodies.
The diagnosis of lymphosarcoma must be made by cytology or histopathology. Cytologic diagnosis is sometimes difficult due to the frequency of blood contamination of the aspirates.
Treatment and Control
There is no treatment for viral infection or for lymphosarcoma in cattle, although parenteral corticosteroids can transiently decrease the severity of clinical signs. Eradication programs have been developed but have achieved variable success, due primarily to expense and the high prevalence of infection among cattle in the USA relative to the economic cost of disease. The most commonly recommended eradication protocol is: 1) identify infected animals using a serologic test, 2) cull seropositive animals immediately, 3) retest the herd in 30–60 days, and 4) use PCR to test young calves and as a complementary test for clarifying test results in herds with a low prevalence of infection. Testing and culling is repeated until the entire herd tests negative. Testing is then repeated every 6 mo. The herd is declared free when there have been no positive tests for 2 yr. Additions to the herd should have 2 negative tests 30 and 60 days prior to arrival.
When test and cull programs are economically untenable, test and segregation programs have been recommended but are rarely implemented. These programs necessitate running 2 completely separate operations and require additional resources, including money, time, and available work force.
Eliminating the movement of blood from infected animals to naive animals is the cornerstone of prevention protocols. In calves, feeding colostrum from seronegative cows is often advocated. However, most epidemiologic evidence suggests that the protective effect of colostral antibody outweighs the risk of infections, particularly in high prevalence herds. The replacement of whole milk feeding with high-quality milk replacer may also be considered. Bloody milk should never be fed to calves.
Cautery or other bloodless methods of dehorning should be used. Equipment used for castration, tattooing, ear tagging, or implanting should be adequately cleaned and disinfected between animals if they are expected to live past 2 yr of age.
Transmission can be decreased in adult cattle by using a fresh rectal sleeve whenever blood is visible on the sleeve or by using single-use rectal sleeves. Artificial insemination or embryo transfer (using negative recipients) may limit transmission. In beef herds, the use of a negative bull may limit transmission, but natural service is an uncommon method of viral transmission unless breeding is traumatic.
Recommendations regardless of animal age include disinfection of equipment that has come in contact with blood or body tissue. Single use, disposable needles should always be used for blood collection and IM injections. It is preferable to use single use disposable needles for vaccination, but the risk of transmitting BLV virus via SC vaccination is low. Handling facilities that become contaminated with blood should be cleaned between animals. Fly control will help minimize the potential for tabanid-associated transmission. Blood transfusions and vaccines containing blood, such as those used for babesiosis and anaplasmosis, are particularly potent means of spreading the disease, and donors must be carefully screened.
Last full review/revision March 2012 by Dusty W. Nagy, DVM, MS, PhD, DACVIM